Abstract : Generalized Pustular Psoriasis (GPP) is a rare autoinflammatory disease characterized by extensive neutrophilic pustular eruptions accompanied by potentially fatal systemic symptoms. To analyzed the clinical profile, therapeutic response, and management strategies of GPP with biological agents. A review of 27 GPP cases from 2020-2025 publications, evaluating demographics, laboratory/histopathological findings, severity assessment, and biologic therapy. The majority of patients were female (70%), aged 18-65 years, with a history of psoriasis vulgaris/GPP. Laboratory findings included leucocytosis, elevated CRP, hypoalbuminemia, thrombocytosis and anemia. Histopathology showed Kogoj spongiform pustules. Severity was assessed using GPPASI, PGA, and DLQI. Secukinumab was the most common biological agent (37%), followed by spesolimab, certolizumab pegol, and infliximab. Biologic therapy was also applied in pregnant patients with dose patterns and combinations tailored to individual responses. Biologic agents are effective in the management of GPP, emphasizing the importance of a personalized approach for optimal outcomes.